KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
November 23, 2015
FYI: Contact: Andrew Goldman (andrew.goldman@keionline.org) or Zack Struver (zack.struver@keionline.org)
Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine for the treatment of the hepatitis C virus (HCV), and offers comments on the agreement.
Continue Reading →